scholarly journals Multiple primary malignancies involving lung cancer

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Feng Li ◽  
Wen-Zhao Zhong ◽  
Fei-Yu Niu ◽  
Ning Zhao ◽  
Jin-Ji Yang ◽  
...  
2020 ◽  
pp. 030089162093367
Author(s):  
Luigi Ventura ◽  
Paolo Carbognani ◽  
Letizia Gnetti ◽  
Maurizio Rossi ◽  
Marcello Tiseo ◽  
...  

Objective: Currently, unlike earlier years, patients affected by multiple primary malignancies (MPM) are significantly increased, thus representing a clinical-pathologic category worthy of attention. Their clinical features and prognosis still need to be studied thoroughly, and this is the aim of our study. Methods: Patients with MPM involving lung cancer admitted in our center between January 2006 and December 2016 were considered. Parametric and nonparametric testing was used for statistical comparisons. Univariate and multivariate analysis was used to evaluate the variables associated with a prognostic value. Results: MPM incidence was 19.8%. Among the 222 patients with MPM enrolled, 204 (91.8%) had two malignancies, while 18 (8.2%) had three malignancies, 38 (17.1%) were synchronous, 41 (18.5%) had lung cancer first (LCF) and 181 (81.5%) had other cancer first (OCF). A significant difference between the time of first cancer diagnosis to the second cancer diagnosis in the LCF vs OCF group was found (median 32 vs 51 months; p-value: 0.038). The most frequent anatomical sites of malignancies preceding or following lung cancer were prostate, colorectal, bladder, and larynx. Multivariate analysis revealed that sex, histologic pattern, and time and order of occurrence were independent factors for overall survival, with male sex, squamous cell lung carcinoma, synchronous and LCF MPM significantly associated with poorer overall survival. Conclusions: Prostate, colorectal, bladder, and larynx were the most frequent anatomical sites of malignancies preceding or following lung cancer. Male sex, squamous cell lung carcinoma, synchronous and LCF MPM might be associated with poorer prognosis.


Lung Cancer ◽  
2002 ◽  
Vol 35 (2) ◽  
pp. 189-194 ◽  
Author(s):  
Yung-Yang Liu ◽  
Yuh-Min Chen ◽  
Sang-Hue Yen ◽  
Chun-Ming Tsai ◽  
Reury-Perng Perng

Surgery Today ◽  
2018 ◽  
Vol 49 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Hiroaki Komatsu ◽  
Nobuhiro Izumi ◽  
Takuma Tsukioka ◽  
Hidetoshi Inoue ◽  
Kantaro Hara ◽  
...  

2015 ◽  
Vol 54 (3) ◽  
pp. 325-331 ◽  
Author(s):  
Shiro Fujita ◽  
Katsuhiro Masago ◽  
Jumpei Takeshita ◽  
Yosuke Togashi ◽  
Akito Hata ◽  
...  

Respiration ◽  
2006 ◽  
Vol 74 (2) ◽  
pp. 192-195 ◽  
Author(s):  
Shuji Haraguchi ◽  
Masafumi Hioki ◽  
Kiyoshi Koizumi ◽  
Takao Hisayoshi ◽  
Tomomi Hirata ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0185485 ◽  
Author(s):  
Shan Shan ◽  
Jun She ◽  
Zhi-qiang Xue ◽  
Chun-xia Su ◽  
Shen-xiang Ren ◽  
...  

Surgery Today ◽  
2007 ◽  
Vol 37 (5) ◽  
pp. 375-378 ◽  
Author(s):  
Shuji Haraguchi ◽  
Kiyoshi Koizumi ◽  
Masafumi Hioki ◽  
Takao Hisayoshi ◽  
Tomomi Hirata ◽  
...  

2017 ◽  
Vol 10 (3) ◽  
pp. 802-808
Author(s):  
Teppei Yamaguchi ◽  
Kazuo Sakurai ◽  
Makoto Kuroda ◽  
Kazuyoshi Imaizumi ◽  
Toyoaki Hida

Nivolumab is a humanized IgG4 and programmed death 1 (PD-1) monoclonal antibody that has demonstrated antitumor efficacy in clinical trials of various malignant tumors including non-small-cell lung cancer and head and neck squamous cell carcinoma (SCC). However, patients with multiple primary malignancies were excluded in clinical trials. Thus, the efficacy of nivolumab in such patients has not been revealed yet. The programmed death ligand 1 (PD-L1) expression level is currently the main predictive biomarker of PD-1 inhibitors in various types of solid tumors and hematological malignancies. Here we describe a patient with synchronous double primary carcinomas of hypopharyngeal SCC and lung adenocarcinoma who exhibited different responses to nivolumab. After nivolumab treatment, hypopharyngeal SCC with moderate PD-L1 positivity by immunohistochemical staining showed a remarkable response; conversely, nivolumab was not effective against lung adenocarcinoma, which was negative for PD-L1. This suggests that tumors with different PD-L1 expressions may exhibit different responses to PD-1 inhibitors when multiple primary malignancies are present within one patient.


Sign in / Sign up

Export Citation Format

Share Document